Personalized medicine in epilepsy patients

Abstract

The large number of different syndromes and seizure types together with an interindividual variable response to antiepileptic drugs (AEDs) make the treatment of epilepsy challenging. Fortunately, the last few years have been characterized by a huge interest in epilepsy genetics and two methods, genome-wide analyses and next-generation sequencing, have definitely given the possibility to write a new chapter in the book of treatment of epilepsy, the chapter on precision medicine. Epilepsy offers a good opportunity for the personalization of therapy if we consider that at least one third of epileptic patients do not achieve complete seizure control with the currently available pharmacological treatments, treatment is still often empirical and precise therapy, based on the pathogenesis and the mechanism of each AED is not generally possible because this mechanism often remains incompletely known. In addition, new drugs are often not targeted but developed using in vivo seizure models, to be potentially used by the largest number of patients. This method leads to a therapy aimed at treating the symptoms and the seizures rather than the single pathogenic mechanism of each seizure type or syndrome. In this narrative review, we summarize the established evidence regarding pharmacogenomics in epilepsy and discuss the basis of precision medicine.

Keywords

Precision medicine / epilepsy treatment / antiepileptic drugs / next generation sequencing / pharmacogenomics in epilepsy

References

[1] FisherRS,ArzimanoglouA,CrossJH.How long for epilepsy remission in the ILAE definition?.Epilepsia2017;58:1486-7

[2] StrianoP.Mutations in mTOR pathway linked to megalencephaly syndromes..Nat Rev Neurol2012;8:542-4

[3] DuncanJS,SisodiyaSM.Adult epilepsy..Lancet2006;367:1087-100

[4] GuerriniR.Epilepsy in children..Lancet2006;367:499-524

[5] PeruccaE.The pharmacological treatment of epilepsy in adults..Lancet Neurol2011;10:446-56

[6] StrianoP,MazzocchettiC,ZaraF..Management of genetic epilepsies: from empirical treatment to precision medicine..Pharmacol Res2016;107:426-9

[7] IoriV,VezzaniA..Epigenetic control of epileptogenesis by miR-146a..Oncotarget2017;8:45040-1 PMCID:PMC5542163

[8] EpiPMConsortium.A roadmap for precision medicine in the epilepsies..Lancet Neurol2015;14:1219-28 PMCID:PMC4663979

[9] BrowneTR.Handbook of Epilepsy.2008;4th ed.PhiladelphiaLippincott Williams & Wilkins

[10] LöscherW,ZimprichF.The clinical impact of pharmacogenetics on the treatment of epilepsy..Epilepsia2009;50:1-23

[11] WalkerLE,YipVLM,PirmohamedM..Personalized medicine approaches in epilepsy..J Intern Med2015;277:218-34

[12] Lopez-GarciaMA,Fernando-SerranoH,GrijalvaI.Genetic polymorphisms associated with antiepileptic metabolism..Front Biosci (Elite Ed)2014;6:377-86

[13] CaudleKE,Whirl-CarrilloM,MintzerS.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing..Clin Pharmacol Ther2014;96:542-8 PMCID:PMC4206662

[14] DepondtC,EspelRS,LienardP.A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity..Eur J Neurol2011;18:1159-64

[15] FrancoV.CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects..Expert Opin Drug Metab Toxicol2015;11:1269-79

[16] GotoS,MurataT,UedaN.Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese..Ther Drug Monit2007;29:118-21

[17] PatsalosPN,BourgeoisBF,GlauserTA.Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies..Epilepsia2008;49:1239-76

[18] OkadaY,IshitsuT,HashimotoN.Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance..Ther Drug Monit2008;30:540-3

[19] SadequeAJ,KorzekwaKR,RettieAE.Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid..J Pharmacol Exp Ther1997;283:698-703

[20] BűdiT,NagyA,KissÁ.Clinical significance of CYP2C9-status guided valproic acid therapy in children..Epilepsia2015;56:849-55

[21] WangC,YangLP,YangX.Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy..Epilepsy Res2017;132:64-9

[22] InoueK,YazawaR,TakahashiT.Influence of uridine diphosphate glucuronosyltransferase 2B7-161C > T polymorphism on the concentration of valproic acid in pediatric epilepsy patients..Ther Drug Monit2014;36:406-9

[23] PosnerJ,LandG,PeckAW.The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert’s syndrome)..Br J Clin Pharmacol1989;28:117-20 PMCID:PMC1379979

[24] WangQ,DongY,QiuF.Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy..Drug Metab Pharmacokinet2015;30:209-13

[25] ChangY,ZhangMC.Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China..Eur J Clin Pharmacol2014;70:941-6

[26] HermannR,MunzelU,FuhrU.The role of Gilbert’s syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine..Pharmacogenomics J2006;6:211-9

[27] TompsonDJ.Clinical Pharmacokinetics of retigabine/ezogabine..Curr Clin Pharmacol2013;8:319-31

[28] MoshéSL,RyvlinP.Epilepsy: new advances..Lancet2015;385:884-98

[29] SisodiyaSM.Genetics of antiepileptic drug resistance..Curr Opin Neurol2009;22:150-6

[30] DallasS,BendayanR..Multidrug resistance-associated proteins: expression and function in the central nervous system..Pharmacol Rev2006;58:140-61

[31] PotschkaH.Pharmacoresistance..Handb Clin Neurol2012;108:741-57

[32] SiddiquiA,WealeME,SmithA.Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1..N Engl J Med2003;348:1442-8

[33] HaerianBS,MohamedEH.Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy..Seizure2011;20:387-94

[34] MannaI,LabateA,FerlazzoE..Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy..Seizure2015;24:124-6

[35] BournissenFG,JuurlinkDN,WalkerM.Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis..Epilepsia2009;50:898-903

[36] KeangpraphunT,ChinvarunY.Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy..J Clin Pharm Ther2015;40:315-9

[37] ChouchiM,KlaaH,TurkiIB.Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in epilepsy: updated systematic review and meta-analysis..BMC Neurol2017;17:32 PMCID:PMC5311838

[38] KimDW,ChuK,YuKS.Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy..Epilepsy Res2009;84:86-90

[39] UferM,MuhleH,HaenischS.Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C > T polymorphism in young and adult patients with epilepsy..Pharmacogenet Genomics2009;19:353-62

[40] SunY,YangK,LiX.Neural overexpression of multidrug resistance-associated protein 1 and refractory epilepsy: a meta-analysis of nine studies..Int J Neurosci2016;126:308-17

[41] TateSK,SisodiyaSM,SchorgeS.Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin..Proc Natl Acad Sci U S A2005;102:5507-12 PMCID:PMC556232

[42] BaghelR,KaurH,RawatC.Evaluating the role of genetic variants on first-line antiepileptic drug response in North India: significance of SCN1A and GABRA1 gene variants in phenytoin monotherapy and its serum drug levels..CNS Neurosci Ther2016;22:740-57

[43] KruegerDA,HollandK,TudorC.Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis..N Engl J Med2010;363:1801-11

[44] HaerianBS,KwanP.SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis..Pharmacogenomics2013;14:1153-66

[45] BrunklausA,ReaveyE,ZuberiSM.Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome..Brain2012;135:2329-36

[46] DalicL,RouletPerez E.Lamotrigine can be beneficial in patients with Dravet syndrome..Dev Med Child Neurol2015;57:200-2

[47] ZhouBT,YinJY,QuJ.Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up..CNS Neurosci Ther2012;18:566-72

[48] QuJ,YangZQ,ZhouBT.Gene-wide tagging study of the association between KCNT1 polymorphisms and the susceptibility and efficacy of genetic generalized epilepsy in Chinese population..CNS Neurosci Ther2014;20:140-6

[49] LynchJM,KinironsP,CavalleriGL.No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy..Epilepsy Res2009;83:44-51

[50] GuoY,QuQ,ChenZG.Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies..PLoS One2015;10:e0124896 PMCID:PMC4395153

[51] PianaC,DellaPasqua O.Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs..Expert Opin Drug Metab Toxicol2014;10:341-58

[52] ChengCY,ChenCH,DengST.HLA associations and clinical implications in T-Cell mediated drug hypersensitivity reactions: an updated review..J Immunol Res2014;2014:565320 PMCID:PMC4034438

[53] ChungWH,HongHS,YangLC.Medical genetics: a marker for Stevens-Johnson syndrome..Nature2004;428:486

[54] TangamornsuksanW,SomkruaR,TassaneeyakulW..Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis..JAMA Dermatol2013;149:1025-32

[55] ChenP,LuCS,HsiehPF.Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan..N Engl J Med2011;364:1126-33

[56] AmstutzU,RiederMJ,FungV.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions..Epilepsia2014;55:496-506

[57] LeckbandSG,DunnenbergerHM,TranE.Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing..Clin Pharmacol Ther2013;94:324-8 PMCID:PMC3748365

[58] FerrellPB Jr.Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations..Pharmacogenomics2008;9:1543-6 PMCID:PMC2586963

[59] CheungYK,ChanEJ,NgMH.HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese..Epilepsia2013;54:1307-14

[60] HungSI,LiuZS,HsihMS.Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese..Pharmacogenomics2010;11:349-56

[61] McCormackM,BourgeoisS,KasperavičiūtėD.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans..N Engl J Med2011;364:1134-43 PMCID:PMC3113609

[62] OzekiT,YowangA,KuboM.Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population..Hum Mol Genet2010;20:1034-41

[63] KaniwaN.The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review..Ther Adv Drug Saf2013;4:246-53 PMCID:PMC4125310

[64] GeninE,HungSI,SchumacherM.HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis..Pharmacogenomics J2014;14:281-8

[65] PlumptonCO,AlfirevicA,PirmohamedM.Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy..Epilepsia2015;56:556-63

[66] WangW,WuXT,YanB.Genetic predictors of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by aromatic antiepileptic drugs among the Chinese Han population..Epilepsy Behav2014;37:16-9

[67] WangQ,XieM,LiX.Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis..Epilepsy Res2017;135:19-28

[68] StrianoP.Epilepsy towards the next decade: new trends and hopes in epileptology.2014;ChamSpringer

[69] ReidCA,BerkovicSF.New therapeutic opportunities in epilepsy: a genetic perspective..Pharmacol Ther2010;128:274-80

[70] MøllerRS,HelbigI..The contribution of next generation sequencing to epilepsy genetics..Expert Rev Mol Diagn2015;15:1531-8

[71] MyersCT.Advancing epilepsy genetics in the genomic era..Genome Med2015;7:91 PMCID:PMC4549122

[72] CovanisA.Clinical management of epileptic encephalopathies of childhood and infancy..Expert Rev Neurother2014;14:687-701

[73] StrianoP.New and investigational antiepileptic drugs..Expert Opin Investig Drugs2009;18:1875-84

[74] StrianoP,MinettiC.Refractory, life-threatening status epilepticus in a 3-year-old girl..Lancet Neurol2008;7:278-84

[75] StrianoP,ZaraF..Genetic epileptic encephalopathies: is all written into the DNA?.Epilepsia2013;54:22-6

[76] BrunklausA.Dravet syndrome-from epileptic encephalopathy to channelopathy..Epilepsia2014;55:979-84

[77] BalestriniS.Pharmacogenomics in epilepsy..Neurosci Lett2018;667:27-39 PMCID:PMC5846849

[78] CeulemansB,MarchauF,LagaeL..Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine..Epilepsia2016;57:e129-34

[79] CeulemansB,LeyssensK,NeelsP.Successful use of fenfluramine as an add-on treatment for Dravet syndrome..Epilepsia2012;53:1131-9

[80] McCannUD,RubinLJ.Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence..JAMA1997;278:666-72

[81] DahlCF,UriePM.Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals..BMC Med2008;6:34 PMCID:PMC2585088

[82] FullerRW,RobertsonDW.Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release..Pharmacol Biochem Behav1988;30:715-21

[83] DindayMT.Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of Dravet syndrome..eNeuro2015; PMCID:PMC4596025

[84] ZhangY,CopmansD,CrawfordAD.Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine..PLoS One2015;10:e0125898 PMCID:PMC4428833

[85] PiersonTM,MarshED,AdamsDR.GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine..Ann Clin Transl Neurol2014;1:190-8 PMCID:PMC4019449

[86] MøllerRS,LarsenLH,RicosMG.Mutations in KCNT1 cause a spectrum of focal epilepsies..Epilepsia2015;56:e114-20 PMCID:PMC5915334

[87] MilliganCJ,GazinaEV,NairU.KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine..Ann Neurol2014;75:581-90 PMCID:PMC4158617

[88] MikatiMA,CarboniM,PetrovskiS.Quinidine in the treatment of KCNT1-positive epilepsies..Ann Neurol2015;78:995-9 PMCID:PMC4811613

[89] EngelsenBA,KarlsenB,LaegreidLM.POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection..Brain2008;131:818-28

[90] DaciA,VllasaliuD,GovoriV.Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients..PLoS One2015;10:e0142408 PMCID:PMC4640545

[91] MaCL,JiaoZ,WuZY.SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy..Pharmacogenomics2015;16:347-60

[92] GroverS,Gourie-DeviM,BalaK.Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy..Pharmacogenomics2010;11:1525-34

[93] TalwarP,MahendruS,GroverS.Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective..Pharmacogenomics J2017;17:242-51

[94] FranzDN,MaysM,CareMM.Everolimus for subependymal giant cell astrocytoma: 5-year final analysis..Ann Neurol2015;78:929-38 PMCID:PMC5063160

[95] MarsanE,SchrammA,MuracaG.Depdc5 knockout rat: a novel model of mTORopathy..Neurobiol Dis2016;89:180-9

[96] GalanopoulouAS,CepedaC..Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target..Epilepsia2012;53:1119-30 PMCID:PMC3389589

[97] SchefferIE,ReganBM,CromptonDE.Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations..Ann Neurol2014;75:782-7

[98] PaemkaL,EhaidebSN,TanMC.Seizures are regulated by ubiquitin-specific peptidase 9 X-linked (USP9X), a de-ubiquitinase..PLoS Genet2015;11:e1005022 PMCID:PMC4357451

[99] De VivoDC,WangD..Glucose transporter 1 deficiency syndrome and other glycolytic defects..J Child Neurol2002;17:3S15-23

[100] SimeoneKA,RhoJM.Ketogenic diet treatment increases longevity inKcna1-null mice, a model of sudden unexpected death in epilepsy..Epilepsia2016;57:e178-82 PMCID:PMC4972642

[101] De GiorgisV.GLUT1 deficiency syndrome 2013: current state of the art..Seizure2013;22:803-11

[102] MillsPB,JakobsC,BaxterP.Mutations in antiquitin in individuals with pyridoxine-dependent seizures..Nat Med2006;12:307-9

[103] ZuberiSM.Epilepsy in 2017: precision medicine drives epilepsy classification and therapy..Nat Rev Neurol2018;14:67-8

[104] DevinskyO,FriedmanD,LauxL.Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial..Lancet Neurol2016;15:270-8

[105] DevinskyO,LauxL,MillerI.Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome..N Engl J Med2017;376:2011-20

[106] O’CallaghanFJ,AlberFD,JohnsonAL.Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial..Lancet Neurol2017;16:33-42

[107] EunsonLH,ZuberiSM,PanayiotopoulosCP.Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability..Ann Neurol2000;48:647-56

[108] RajakulendranS,KullmannDM.Episodic ataxia type 1: a neuronal potassium channelopathy..Neurotherapeutics2007;4:258-66

[109] WrightS,HwangY.Seizure phenotypes, periodicity, and sleep-wake pattern of seizures in Kcna-1 null mice..Epilepsy Behav2016;55:24-9

[110] RoundtreeHM,JohnsonC,SamsonKK.Orexin receptor antagonism improves sleep and reduces seizures in Kcna1-null mice..Sleep2016;39:357-68 PMCID:PMC4712395

[111] MishraV,GautierNM,HutsonTN.Scn2a deletion improves survival and brain-heart dynamics in the Kcna1-null mouse model of sudden unexpected death in epilepsy (SUDEP)..Hum Mol Genet2017;26:2091-103 PMCID:PMC6075631

[112] GardellaE,TrivisanoM,AlberM.The phenotype of SCN8A developmental and epileptic encephalopathy..Neurology2018;91:e1112-24

[113] AnandG,OrsiniA,JayapalS.Autosomal dominant SCN8A mutation with an unusually mild phenotype..Eur J Paediatr Neurol2016;20:761-5

[114] GardellaE,MøllerRS,LemkeJR.Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation..Ann Neurol2016;79:428-36

[115] AndersonLL,HawkinsNA,PetersohnAA.Antiepileptic activity of preferential inhibitors of persistent sodium current..Epilepsia2014;55:1274-83 PMCID:PMC4126848

[116] Lopez-SantiagoLF,WagnonJL,FrasierCR.Neuronal hyperexcitability in a mouse model of SCN8A epileptic encephalopathy..Proc Natl Acad Sci U S A2017;114:2383-8 PMCID:PMC5338511

[117] PatelRR,BrustovetskyT,CumminsTR.Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol..Brain2016;139:2164-81 PMCID:PMC4958898

[118] WatanabeY.Inhibitory effect of amiodarone on Na(+)/Ca(2+) exchange current in guinea-pig cardiac myocytes..Br J Pharmacol2000;131:80-4 PMCID:PMC1572287

[119] WatanabeY.Blocking effect of bepridil on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes..Jpn J Pharmacol2001;85:370-5

[120] WatanabeY,ShigekawaM.Inhibitory effect of aprindine on Na+/Ca2+ exchange current in guinea-pig cardiac ventricular myocytes..Br J Pharmacol2002;136:361-6 PMCID:PMC1573359

[121] YamakawaT,WatanabeH.Inhibitory effect of cibenzoline on Na+/Ca2+ exchange current in guinea-pig cardiac ventricular myocytes..J Pharmacol Sci2012;120:59-62

[122] PenaSD.Ataxia and myoclonic epilepsy due to a heterozygous new mutation in KCNA2: proposal for a new channelopathy..Clin Genet2015;87:e1-3

[123] JouvenceauA,SpauschusA,ZuberiSM.Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel..Lancet2001;358:801-7

[124] XieG,ClapcoteSJ,ZhangJY.A new Kv1.2 channelopathy underlying cerebellar ataxia..J Biol Chem2010;285:32160-73 PMCID:PMC2952217

[125] ImbriciP,EunsonLH,HerdC.Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia..Brain2004;127:2682-92

[126] DamajL,LortieA,OspinaLH.CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms..Eur J Hum Genet2015;23:1505-12 PMCID:PMC4613477

[127] Hino-FukuyoN,Arai-IchinoiN,SatoR.Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome..Hum Genet2015;134:649-58

[128] ReinsonK,TalvikI,ÕunapuuA.Biallelic CACNA1A mutations cause early onset epileptic encephalopathy with progressive cerebral, cerebellar, and optic nerve atrophy..Am J Med Genet A2016;170:2173-6

[129] CramerSW,CarterRE,EbnerTJ.Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse..J Neurosci2015;35:5664-79 PMCID:PMC4388925

[130] ZamponiGW.Targeting voltage-gated calcium channels in neurological and psychiatric diseases..Nat Rev Drug Discov2016;15:19-34

[131] SongI,ChoiS,KimY.Role of the 1G T-type calcium channel in spontaneous absence seizures in mutant mice..J Neurosci2004;24:5249-57

[132] NavaC,RastetterA,de KovelCG.De novo mutations in HCN1 cause early infantile epileptic encephalopathy..Nat Genet2014;46:640-5

[133] SavelievaI.CammA.Novel If current inhibitor ivabradine: safety considerations..Heart rate slowing by If current inhibition.2006;BaselKarger79-96

[134] CacheauxLP,TibbsGR,LeviR.Impairment of hyperpolarization-activated, cyclic nucleotide-gated channel function by the intravenous general anesthetic propofol..J Pharmacol Exp Ther2005;315:517-25

[135] LyashchenkoAK,YangJ.Propofol inhibits HCN1 pacemaker channels by selective association with the closed states of the membrane embedded channel core..J Physiol2007;583:37-56 PMCID:PMC2277223

[136] PoolosNP,JohnstonD..Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites..Nat Neurosci2002;5:767-74

[137] SurgesR,FeuersteinTJ.Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells..Epilepsia2003;44:150-6

[138] StraussU,BräuerAU,BajoratR.An impaired neocortical Ih is associated with enhanced excitability and absence epilepsy..Eur J Neurosci2004;19:3048-58

[139] GhasemiM.Pathologic role of neuronal nicotinic acetylcholine receptors in epileptic disorders: implication for pharmacological interventions..Rev Neurosci2015;26:199-223

[140] BecchettiA,MeneghiniS,AmadeoA..The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy..Front Physiol2015;6:22 PMCID:PMC4324070

[141] HowellKB,DalzielK,MandelstamS.A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy..Epilepsia2018;59:1177-87 PMCID:PMC5990455

[142] CórdobaM,VegaPA,Perez-MaturoJ.Whole exome sequencing in neurogenetic odysseys: an effective, cost- and time-saving diagnostic approach..PLoS One2018;13:e0191228 PMCID:PMC5794057

[143] OrsiniA,StrianoP..Recent advances in epilepsy genetics..Neurosci Lett2018;667:4-9